Amidrine Disease Interactions
There are 7 disease interactions with Amidrine (acetaminophen / dichloralphenazone / isometheptene mucate).
Acetaminophen (applies to Amidrine) alcoholism
Major Potential Hazard, High plausibility.
Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.
Acetaminophen (applies to Amidrine) liver disease
Major Potential Hazard, Moderate plausibility. Applicable conditions: Malnourished, Dehydration
Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.
Anxiolytics/sedatives/hypnotics (applies to Amidrine) depression
Major Potential Hazard, Moderate plausibility.
A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.
Isometheptene mucate (applies to Amidrine) vascular effects
Major Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension, Hypertension, Renal Dysfunction, Liver Disease
The use of combination drugs that have isometheptene mucate may be contraindicated in patients with glaucoma and/or severe cases of renal disease, hypertension, organic heart disease, or hepatic disease.
Acetaminophen (applies to Amidrine) PKU
Moderate Potential Hazard, High plausibility. Applicable conditions: Phenylketonuria
Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).
Anxiolytics/sedatives/hypnotics (applies to Amidrine) glaucoma
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension, Urinary Retention
Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.
Anxiolytics/sedatives/hypnotics (applies to Amidrine) liver disease
Moderate Potential Hazard, Moderate plausibility.
In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.
Amidrine drug interactions
There are 442 drug interactions with Amidrine (acetaminophen / dichloralphenazone / isometheptene mucate).
Amidrine alcohol/food interactions
There are 2 alcohol/food interactions with Amidrine (acetaminophen / dichloralphenazone / isometheptene mucate).
More about Amidrine (acetaminophen / dichloralphenazone / isometheptene mucate)
- Check interactions
- Compare alternatives
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: antimigraine agents
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.